Comparing Costs of Hemodialysis and Peritoneal Dialysis

Jonathan W. Cunningham and Ajay K. Singh discuss the results of their study, "Daprodustat and Heart Failure in CKD," with JASN Deputy Editor David H. Ellison.

Susan R. Mendley and Chyng-Wen Fwu discuss the findings of their study, "Age- and Race-Specific Changes in ESKD Incidence over Four Decades," with JASN Editor-in-Chief Rajnish Mehrotra.

In this podcast, outgoing Editor-in-Chief Josie Briggs talks with incoming Editor-in-Chief Raj Mehrotra about his vision for the next chapter of JASN.

Dr. Briggs and Brendon Neuen discuss his paper in the December issue of JASN. This article on the CREDENCE and EMPA-CKD clinical trials shows that SGLT2 inhibitors allow more consistent use of RAS blockade in patients with declining renal function.

In this podcast, EIC Josie Briggs talks with Associate Editor John Gill about the valuable data resources for research on kidney transplantation. Drs. Gill and Briggs provide some advice for users of these important resources.

In this podcast, EIC Josie Briggs talks with Giuseppe Remuzzi about the NEPHSTROM Trial & the next steps in translational work to test the possibility that mesenchymal stem cells can be used as a therapeutic agent to promote repair of kidney damage.

In the podcast, EIC Josie Briggs discusses a paper entitled "Structural Racism, Historical Redlining, and Incidence of Kidney Failure in US Cities" with co-authors Kevin Nguyen and Deidre Crews.

In the episode, EIC Josie Briggs discusses a randomized control trial addressing the impact of sodium bicarbonate on the vascular dysfunction in CKD and an observational case control study of the impact of antibiotic use on kidney stone formation.

In this podcast, Dr. Josie Briggs discusses with Dr. Andrew Rule his latest study showing the need to revise our estimate of the number of nephrons in the human kidney.

In this episode, JASN Associate Editor Katalin Susztak talks with Dr. Susan Quaggin about work from her laboratory on ischemic injury and translational targets in the Angiopoietin-Tie 2 pathway.